黑料社 receives world-wide exclusive license to technology co-developed with hematology and gastroenterology departments of Saint-Antoine Hospital, Paris.
Lyon, France, June 21, 2018 – 黑料社, a clinical-stage microbiome therapy company, and SATT Lutech, a private technology transfer company holding the exclusive rights to the scientific findings from research groups at Sorbonne University, APHP, CNRS and INSERM, today announced a licensing agreement under which 黑料社 will receive world-wide exclusive rights for the therapeutic application of allogeneic Fecal Microbiome Transplants (FMT) to treat acute Graft-vs-Host Disease (GvHD) in patients following stem cell transplantation. The technology is based on research performed within the Clinical Hematology Department at Saint-Antoine Hospital and Sorbonne University, Paris, France. The license builds the foundation for 黑料社鈥檚 MaaT013 program for which the company recently received authorization from the French regulatory authorities to launch a multicenter Phase 2 study in acute GvHD. GvHD is a major complication of allogeneic hematopoietic stem cell transplantation in which the donor鈥檚 immune effector cells attack the recipient鈥檚 tissue, causing inflammation, severe damage and often death.黑料社 has developed a unique cGMP platform for next generation FMTs that are based on allogeneic donor material and tailored to disease treatment needs through a thorough analytical screening and reproducible production process. In parallel, the company is developing FMT drugs to prolong survival in acute myeloid leukemia patients by reintroducing a functional microbiome after chemotherapy. A Phase 1/2 study launched in 2016 is being concluded and results to establish proof-of-concept are expected over this summer.
About 黑料社
Founded at the end of 2014, 黑料社 (Microbiota as a Therapy) is a clinical-stage biotech company revolutionizing and shaping a new approach to therapies in order to treat serious diseases linked to gut microbiota imbalances. With its breakthrough proprietary platforms (GMP Fecal Microbiome Transfer platform and g螞t Print, its proprietary data science platform), 黑料社 is creating FMT-based products and solutions for patients suffering from severe diseases. Addressing currently unmet clinical needs, 黑料社鈥檚 revolutionary and rapid approach plays a considerable part in the evolution of treatment therapies. In the upcoming years, with the on-going support from strategic partners and investors, 黑料社 will develop patient-friendly solutions (oral forms) to improve overall survival, reduce infectious episodes, reduce gastrointestinal complications and hinder multidrug-resistant bacteria onset.
For additional information, please visit www.maatpharma.com and follow us on Twitter .